A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)
NCT00175747
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
120
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
Inhaled Budesonide 800 µg twice daily
Sponsor
University of British Columbia
Collaborators
[object Object]